Craft

Mallinckrodt Pharmaceuticals

Revenue

$1 B

FY, 2022

Mallinckrodt Pharmaceuticals Summary

Company Summary

Overview
Mallinckrodt Pharmaceuticals is a company that develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. The company operates in two segments: Specialty Brands and Specialty Generics. Specialty Brands includes innovative specialty pharmaceutical brands. Specialty Generics includes niche specialty generics drugs and active pharmaceutical ingredients.
Type
Private
Status
Active
Founded
1867
HQ
Dublin 15, IE | view all locations
Website
https://www.mallinckrodt.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jason Goodson

    Jason Goodson, Executive Vice President and Head of Corporate Development

    • Paul Bisaro

      Paul Bisaro, Chairman of the Board

      • Lisa French

        Lisa French, Executive Vice President and Chief Commercial Officer

        • Andrew Gonce, Senior Director, Commercial Strategy

        LocationsView all

        4 locations detected

        • Dublin 15, D HQ

          Ireland

          College Business & Technology Park, Blanchardstown Rd N

        • Hazelwood, MO

          United States

          675 James S. McDonnell Blvd

        • Webster Groves, MO

          United States

          385 Marshall Ave

        • Staines, England

          United Kingdom

          The Causeway, Staines-upon-Thames

        Mallinckrodt Pharmaceuticals Financials

        Summary Financials

        Revenue (Q3, 2023)
        $497.0M
        Gross profit (Q3, 2023)
        $287.8M
        Net income (Q3, 2023)
        ($1.7B)
        Cash (Q3, 2023)
        $389.8M
        EBIT (Q3, 2023)
        ($1.4B)

        Footer menu